A federal appeals court in Washington, D.C., last week ruled that the sequence of DNA obtained from a known protein is obvious and therefore unpatentable. The court was ruling on a case, In re Kubin, involving a patented gene sequence for the human immune protein NAIL, owned by Amgen Inc. in Thousand Oaks, California. The judges ruled that it took no original insight to work out the gene's code. The decision is the latest blow to gene patents, which are facing increased scrutiny.
展开▼
机译：华盛顿特区的一个联邦上诉法院上周裁定，从一种已知蛋白质获得的DNA序列是显而易见的，因此不能申请专利。法院正在就In re Kubin一案作出裁决，该案涉及加利福尼亚州千橡市的安进公司（Amgen Inc.）拥有的人类免疫蛋白NAIL的专利基因序列。法官裁定，得出该基因的密码并不需要最初的见识。该决定是对基因专利的最新打击，而基因专利正面临越来越严格的审查。
展开▼
